Pfizer's Ibrance Extends Survival by 15 Months in Breast Cancer Patients

Dec 12, 2024, 03:07 PM

Pfizer Inc. has announced that its drug Ibrance, which generates annual sales of $4.3 billion, has shown efficacy in extending median progression-free survival by over 15 months in a Phase 3 study for patients with HR+, HER2+ metastatic breast cancer. This development could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis. The study, known as PATINA, involved combining Ibrance with standard-of-care therapies, marking a potential expansion of its use to a new patient population that represents 10% of breast cancer cases.